Techne (TECH)
has always been a little different in the realm of publicly-traded life
science companies. While the company's headquarters are pretty pleasant
once you're inside, the surroundings are a pretty nondescript
commercial/light industrial zone. Likewise, it's a little strange to sit
down as an analyst with a management team that tells you they will not
do road shows or conference calls, and doesn't much care whether they
get any attention from Wall Street at all.
None of this is meant
as a criticism against the company - management was always unfailingly
polite and helpful to me in my analyst days, and the company's stock has
generated excellent returns over the past 20 and 10 years. Where there
is an issue, though, is in the more recent performance, where Techne has
notably lagged other life sciences companies like Thermo Fisher (TMO), Sigma-Aldrich (SIAL) and more specialized/focused companies like Illumina (ILMN).
I'm
optimistic about the potential for new management to put Techne on a
more growth-oriented footing, not only with an expanded international
focus but also perhaps a wider view of the company's addressable market
opportunities. While I could see bull-case upside into the low $80s for
Techne, that requires a level of transformation that is pretty
aggressive. A more probable trajectory suggests Techne is close to fair
value today, but still offers good near-real time exposure to life
sciences spending.
Please read more here:
Can New Management Drive New Growth At Techne?
No comments:
Post a Comment